leisure time -WSS

leisure time

author：comprehensive 2025-09-30 18:17:43 - browse：45522

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Wegovy, Zepbound and weight loss drugs that preserve muscle

WSS

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Hospitals are piloting generative AI tools as regulators play catch

Surge of respiratory disease in China has likely explanation

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

leisure time

leisure time

focus

Apple is now the first public company to be valued at $3 trillion

David Sabatini, ex

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Weight loss drugs aren’t covered by Obamacare. That may change

Medical leaders decry Supreme Court decision on affirmative action

WATCH: Why do our ears pop?

Affirmative action in medical school literally saved lives

Hospitals are piloting generative AI tools as regulators play catch

United colonoscopy coverage change 'may cost lives,' doctors say

David Sabatini, ex

focus

U.K. considers world's first use of meningitis vaccine to address gonorrhea

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Flagship Pioneering startup Sonata Therapeutics lays off 21

Does good food count as health care? Study aims to find out

Hospitals look to new technology to keep health care workers safe

Poor hospice wound care hurts patients and families

Wikipedia

hotspot

focus

hotspot